Corporate news - Gerresheimer

Corporate news

Revenues up 2.2% to EUR 323.9m (+3.2% at constant exchange rates) Adjusted EBITDA with slight improvement on prior-year quarter at EUR 62.1m Net…
Read more
Revenues up 2.6% to EUR 335.4m (6.0% at constant exchange rates) Adjusted EBITDA rises 9.1% to EUR 65.1m (14.1% at constant exchange rates) Net…
Read more
Dividend raised to EUR 0.70 per share Management Board and Supervisory Board given formal approval by large majority Dr. Axel Herberg new member…
Read more
Düsseldorf/Peachtree City (Georgia/USA), March 10, 2014 – Gerresheimer AG, one of the world’s leading partners of the pharma and healthcare industry,…
Read more
Third-quarter revenues up 1.8% (+4.5% excluding exchange rate effects), to EUR 316.9m Adjusted EBITDA reaches EUR 61.6m (prior-year quarter: EUR…
Read more
Düsseldorf, April 18, 2013 – A dividend of EUR 0.65 per share was approved at the Annual General Meeting of Gerresheimer AG held today in Düsseldorf.…
Read more
Production of components for a further Sanofi insulin pen Düsseldorf, April 16, 2013. Gerresheimer has commenced production of components for another…
Read more
First-quarter revenues up 10.4% to EUR 296.7m Adjusted EBITDA margin reaches 15.5% Net income grows by 41.7% to EUR 10.2m Adjusted earnings per…
Read more
Updated version March 08, 2013 Updated: 6th paragraph, last sentence New: “unlike in previous years” and “not payable tax free” Revenues rise by…
Read more

Contact us!

Communication & Marketing
Phone: +49 211 61 81 251
E-Mail: ueli.utzinger-remove@remove-gerresheimer.com